AR and prostate carcinoma: In order to characterise the role of editing isoforms of miR-379 in a range of prostate cancer cell lines, we selected two androgen receptor (AR)-negative cell lines (PC3 and DU145) and two AR-positive/androgen-responsive cell lines (22Rv1 and LNCaP)26,27.